{
    "doi": "https://doi.org/10.1182/blood.V126.23.4058.4058",
    "article_title": " KIT D816V Mutation Positive Bone Marrow Mesenchymal Stem Cells in Indolent Systemic Mastocytosis Are Associated with Disease Progression ",
    "article_date": "December 3, 2015",
    "session_type": "634. Myeloproliferative Syndromes: Clinical: Poster III",
    "abstract_text": "PURPOSE: Multilineageinvolvement of bone marrow (BM) hematopoiesis by the somatic KIT D816V mutation is present in a subset of adult indolent systemic mastocytosis (ISM) patients in association with a poorer prognosis. Here we investigated the potential involvement of BM mesenchymal stem cells (MSC) from ISM patients by the KIT D816V mutation and its potential impact on disease progression and outcome. METHODS: The KIT D816V mutation was investigated in highly-purified BM MSC and other BM cell populations from 83 ISM patients followed for a median of 116 months. MC clonality was further evaluated in female patients by the pattern of inactivation of the X chromosome (XCIP). RESULTS: KIT D816V-mutated MSC were detected in 22/83 (27%) ISM patients. All MSC-mutated patients had multilineage KIT mutation (100% vs. 30%, p=0.0001) and they more frequently showed involvement of lymphoid plus myeloid BM cells (59% vs 22%; P =.03) and a polyclonal XCIP of the KIT- mutated BM MC (64% vs 0%; P =0.01) vs other multilineage ISM cases. Moreover, presence of KIT D816V-mutated MSC was associated with more advanced disease features of ISM, a greater rate of disease progression (50% vs 17%; P =.04) and a shorter progression-free survival at 10, 20 and 30 years ( P \u2264.003). CONCLUSION: Overall, these results support the notion that ISM patients with mutated MSC may have acquired the KIT mutation in a common pluripotent progenitor cell, prior to differentiation into MSC and hematopoietic precursor cells, before the X-chromosome inactivation process occurs. From a clinical point of view, acquisition of the KIT mutation in an earlier BM precursor cell confers a significantly greater risk for disease progression and a poorer outcome. Disclosures No relevant conflicts of interest to declare.",
    "topics": [
        "bone marrow",
        "disease progression",
        "mastocytosis, indolent systemic",
        "mutation",
        "stem cell, mesenchymal",
        "clonality (genetic analysis)",
        "hematopoietic stem cells",
        "stem cells"
    ],
    "author_names": [
        "Andres C Garcia-Montero, PhD",
        "Maria Jara-Acevedo, MSc",
        "Ivan Alvarez-Twose, MD",
        "Cristina Teodosio",
        "Laura Sanchez-Mu\u00f1oz",
        "Javier Ignacio Mu\u00f1oz-Gonzalez",
        "Andrea Mayado",
        "Almudena Matito, MD PhD",
        "Carolina Caldas",
        "Jose M Morgado, MSc",
        "Luis Escribano, MD PhD",
        "Alberto Orfao, MD PhD"
    ],
    "author_dict_list": [
        {
            "author_name": "Andres C Garcia-Montero, PhD",
            "author_affiliations": [
                "Centro de Investigaci\u00f3n del C\u00e1ncer (IBMCC-CSIC/USAL and IBSAL) and Departamento de Medicina, Universidad de Salamanca, Spain, Salamanca, Spain "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Maria Jara-Acevedo, MSc",
            "author_affiliations": [
                "Centro de Investigaci\u00f3n del C\u00e1ncer (IBMCC-CSIC/USAL and IBSAL) and Departamento de Medicina, Universidad de Salamanca, Spain, Salamanca, Spain "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ivan Alvarez-Twose, MD",
            "author_affiliations": [
                "Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain, Toledo, Spain "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Cristina Teodosio",
            "author_affiliations": [
                "Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands, Rotterdam, Netherlands "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Laura Sanchez-Mu\u00f1oz",
            "author_affiliations": [
                "Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain, Toledo, Spain "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Javier Ignacio Mu\u00f1oz-Gonzalez",
            "author_affiliations": [
                "Centro de Investigaci\u00f3n del C\u00e1ncer (IBMCC-CSIC/USAL and IBSAL) and Departamento de Medicina, Universidad de Salamanca, Spain, Salamanca, Spain "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andrea Mayado",
            "author_affiliations": [
                "Centro de Investigaci\u00f3n del C\u00e1ncer (IBMCC-CSIC/USAL and IBSAL) and Departamento de Medicina, Universidad de Salamanca, Spain, Salamanca, Spain "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Almudena Matito, MD PhD",
            "author_affiliations": [
                "Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain, Toledo, Spain "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carolina Caldas",
            "author_affiliations": [
                "Centro de Investigaci\u00f3n del C\u00e1ncer (IBMCC-CSIC/USAL and IBSAL) and Departamento de Medicina, Universidad de Salamanca, Spain, Salamanca, Spain "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jose M Morgado, MSc",
            "author_affiliations": [
                "Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain, Toledo, Spain "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Luis Escribano, MD PhD",
            "author_affiliations": [
                "Centro de Investigaci\u00f3n del C\u00e1ncer (IBMCC-CSIC/USAL and IBSAL) and Departamento de Medicina, Universidad de Salamanca, Spain, Salamanca, Spain "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alberto Orfao, MD PhD",
            "author_affiliations": [
                "Centro de Investigaci\u00f3n del C\u00e1ncer (CIC, IBMCC USAL-CSIC), Servicio General de Citometr\u00eda, Universidad de Salamanca, Salamanca, Spain"
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-04T15:29:30",
    "is_scraped": "1"
}